Innovative Participation at the Summit
C4 Therapeutics, Inc. (Nasdaq: CCCC), a pioneering biopharmaceutical company based in Watertown, Massachusetts, has excitedly announced its participation in the renowned 7th Annual Targeted Protein Degradation & Induced Proximity Summit. This significant event takes place over several days, bringing together top experts from the biopharmaceutical field to discuss advancements in targeted protein degradation science and its implications for drug development.
Highlights of the Event
At this summit, scheduled from October 28-31, four key leaders from C4 Therapeutics will share their insights through oral presentations and panel discussions. Their contributions aim to highlight the company’s innovative approach in designing digital bioavailable degraders that could revolutionize treatment options for patients globally.
Key Presentations on October 29
One of the key highlights of the summit is a panel discussion titled “CEO Think Tank: A Strategic Look at Targeted Protein Degradation & Induced Proximity Field,” featuring Andrew Hirsch, the president and CEO of C4 Therapeutics. This panel will delve into strategic perspectives on the evolving landscape of protein degradation, shedding light on its future challenges and opportunities.
A comprehensive oral presentation will follow, where Stew Fisher, Ph.D., the chief scientific officer, will provide clinical insights on the use of kinetics-based PKPD modeling. He will explain how such modeling is pivotal in driving the optimization of degraders, showcasing C4T's commitment to enhancing drug efficacy.
Insights on October 30
The next day, attendees can look forward to an oral presentation by Len Reyno, M.D., the chief medical officer. He will present initial clinical data from the ongoing clinical trial of CFT1946, a promising investigational therapy. This presentation aims to disseminate new findings and underline the drug’s potential impact on patient health and treatment resilience.
Furthermore, echoing the spirit of collaboration, Scott Boyle, Ph.D., the chief business officer, will participate in two panels focused on strategic partnerships. These discussions will reveal lessons learned from major partnerships, addressing both platform and asset perspectives, which are crucial for fostering innovation within the therapeutic landscape.
About C4 Therapeutics
C4 Therapeutics (Nasdaq: CCCC) is unwavering in its mission to advance targeted protein degradation science. The company is dedicated to developing transformative medicines that aim to improve patient outcomes significantly. Through its TORPEDO platform, C4 Therapeutics is at the forefront of designing small-molecule medicines that efficiently tackle hard-to-treat diseases by utilizing the body’s inherent protein recycling systems.
Science that Transforms Lives
The degrader medicines being developed aim to quickly eliminate disease-causing proteins, which could lead to breakthroughs in overcoming challenges like drug resistance and addressing traditionally undruggable targets. This innovative approach reflects C4 Therapeutics’ commitment to addressing unmet medical needs and ultimately transforming patients’ lives.
Keeping in Touch with the Company
For those interested in following the developments at C4 Therapeutics, they encourage individuals to explore further through their website for the most current updates on their research progress and upcoming events. The commitment to advancing drug development continues to be a driving force for C4 Therapeutics.
Contact Information
For inquiries related to investor relations, Courtney Solberg serves as the Senior Manager and can be reached directly via email. Media inquiries are handled by Loraine Spreen, the Senior Director of Corporate Communications & Patient Advocacy.
Frequently Asked Questions
What is the focus of C4 Therapeutics?
C4 Therapeutics is focused on advancing targeted protein degradation science and developing new therapeutic medicines.
Who are the key speakers at the summit?
Key speakers include Andrew Hirsch, Stew Fisher, Len Reyno, and Scott Boyle, each presenting on different aspects of protein degradation.
When is the 7th Annual Summit taking place?
The summit takes place from October 28-31, showcasing various breakthroughs in the industry.
How does C4 Therapeutics contribute to patient health?
The company develops degrader medicines designed to target and eliminate harmful proteins, improving patient outcomes.
Where can I find more information about C4 Therapeutics?
More information is available on their official website, providing updates on research and clinical advancements.
